AZ bets billions on Daiichi’s ADC therapy 28-Jul-2020 By Ben Hargreaves AZ agrees deal with Daiichi to co-develop a treatment in oncology, as part of its ADC strategy.
Daiichi pays $225m to access gene therapy production platform 06-Apr-2020 By Ben Hargreaves Daiichi partners with Ultragenyx to utilize its HeLa producer cell line platform for commercial-scale gene therapy production.
AZ’s ADC receives priority review 17-Oct-2019 By Ben Hargreaves US FDA provides AZ and Daiichi Sankyo’s ADC for the treatment of metastatic breast cancer priority review, with a decision set for Q2 2020.
Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC 03-Aug-2018 By Maggie Lynch Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.
Daiichi Sankyo: looming Benicar patent loss and large molecule focus prompted plant closure 06-Apr-2016 By Gareth Macdonald Closure of its Benicar intermediates plant was prompted by impending US patent loss and a decision to focus on large molecule drugs says Daiichi Sankyo.
